Figures
Abstract
Background
Fish oil (FO) is rich in n-3 polyunsaturated fatty acids (PUFA), which have been suggested to be anti-inflammatory and are associated with improvement of several inflammatory diseases. In this study, we investigated the influence of FO on allergen-induced lung inflammation and airway hyperreactivity in mice.
Methods
Male A/J mice were fed either a standard-chow (SC) or a FO diet (FO) for 8 weeks. After 4 weeks, each group was further randomized for ovalbumin (SC-OVA and FO-OVA) or saline (SC-SAL and FO-SAL) challenge. Resistance and elastance were measured at baseline and after aerosolized methacholine, 24h after the last challenge. Bronchoalveolar lavage (BAL) was performed for leukocyte counts. Lung tissue mucus deposition, peribronchiolar matrix deposition and eosinophil infiltration were quantified. Serum immunoglobulin E (IgE) and IgG1 (ref 2.2), lung IL-4, IL-5, IL-10, IL-13, IL-17, INFγ and eotaxin-1 and 2 were detected by ELISA and nuclear factor kappa B (NFκB), GATA-3 and peroxisome proliferator-activated receptor gamma (PPARγ) expression was measured by Western blot.
Results
Levels of serum IgE and IgG1 were significantly higher in OVA sensitized mice. OVA challenge resulted in increased eosinophil infiltration, increased inflammatory cytokine production, peribronchiolar matrix and mucus deposition and airway hyperreactivity to aerosolized methacholine. Elevated lung NFκB and GATA-3 expression was noted in OVA-challenged mice. These changes were attenuated in mice fed with FO diet. Higher PPARγ expression was also detected in the lungs from the FO-fed groups.
Citation: Bargut TCL, Ferreira TPT, Daleprane JB, Martins MA, Silva PMR, Aguila MB (2013) Fish Oil Has Beneficial Effects on Allergen-Induced Airway Inflammation and Hyperreactivity in Mice. PLoS ONE 8(9): e75059. https://doi.org/10.1371/journal.pone.0075059
Editor: Heinz Fehrenbach, Research Center Borstel, Germany
Received: December 26, 2012; Accepted: August 12, 2013; Published: September 6, 2013
Copyright: © 2013 Bargut et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The research was supported by CNPq, Faperj and PAPES4/Fiocruz. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: MBA is currently a PLOS ONE Editorial Board member. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Introduction
Asthma is an inflammatory, chronic airway disease that is characterized by structural and functional changes, and its prevalence is widespread throughout the world [1]. The bronchial asthmatic response is based on a type 2 T helper cytokine (Th2) immune profile with leukocyte infiltration, particularly consisting of eosinophils, which are associated with pulmonary remodeling, goblet cell hyperplasia and mucus hyperproduction [2]. This process is controlled by inflammatory mediators such as cytokines and chemokines, which cause airway hyperreactivity (AHR) and airflow obstruction [3]. However, there is no cure for asthma, and its control requires using anti-inflammatory agents, especially glucocorticoids, which have a broad spectrum of adverse effects. Additionally, 5-10% of asthmatic patients are resistant to glucocorticoids, which supports the need to search for new therapies [4].
Fish oil (FO) is rich in n-3 polyunsaturated fatty acids (PUFA), which include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [5]. EPA and DHA ingestion partially substitute for cell membrane arachidonic acid (a n-6 PUFA) and compete for its degradation enzymes [6]. These mechanisms reduce 2 and 4-series eicosanoid production and enhance 3 and 5-series eicosanoid production, which display less pro-inflammatory activity [7]. Studies from our laboratory demonstrated that FO intake directly diminished cytokine production [8,9] through effects on transcription factors that control inflammatory responses, such as nuclear factor kappa B (NFκB) [10] and peroxisome proliferator-activated receptor (PPAR)-γ [11].
Clinical trials have demonstrated that FO intake reduces biomarkers and improves lung function in asthmatic children [12,13]. Similar effects were observed in adults, with diminished 2-series prostaglandin, 4-series leukotriene, interleukin-1β and tumor necrosis factor (TNF)-α concentrations, thus reducing the necessity for bronchodilators [14]. FO diminished oxidative stress markers in allergen-challenged mice, though its effects on other changes in lung tissue, inflammatory status and function remain uncertain [7,15].
The prophylactic effects of FO intake on allergen-induced airway inflammation in actively sensitized mice have not been studied. Thus, this is the aim of the present study.
Material and Methods
Animals and diet
Male A/J mice (18-20 g) were obtained from Oswaldo Cruz breeding and were maintained under controlled conditions (20 ± 2°C, 60 ± 10% humidity and 12 h dark/light cycle) with free access to food and water. Animals were fed a standard chow (SC; 7% wt/wt soybean oil) or a fish oil diet (FO; 6.3% wt/wt FO + 0.7% wt/wt soybean oil) for 8 weeks (Table 1). All diets were elaborated with purified nutrients by PragSoluções (Jau, São Paulo, Brazil) and were in accordance with the American Institute of Nutrition’s recommendation (AIN 93G) [16]. FO was purchased from Sigma-Aldrich (FO from menhaden fish - Sigma-Aldrich Co., St Louis, MO, USA) and contains 12.9% of EPA and 12% of DHA (EPA/DHA ratio = 1.075). Food intake was measured daily and body mass was assessed weekly. All of the procedures were examined and approved by the Animal Ethics Committee of the Oswaldo Cruz Foundation (CEUA-FIOCRUZ, L034/09) (Rio de Janeiro, Brazil).
| Diet | ||
|---|---|---|
| Content (g/Kg) | SC | FO |
| Casein (≥ 85% of protein) | 200.0 | 200.0 |
| L-Cystine | 3.0 | 3.0 |
| Cornstarch | 529.486 | 529.486 |
| Sucrose | 100.0 | 100.0 |
| Soybean oil | 70.0 | 7.0 |
| Fish oil | - | 63.0 |
| Fiber | 50.0 | 50.0 |
| Vitamin mix* | 10.0 | 10.0 |
| Mineral mix* | 35.0 | 35.0 |
| Choline | 2.5 | 2.5 |
| Antioxidant | 0.014 | 0.014 |
| Total mass | 1,000. 0 | 1,000. 0 |
| Energy content (Kcal/kg) | 3960 | 3960 |
| Carbohydrates (% Energy) | 64 | 64 |
| Proteins (% Energy) | 19 | 19 |
| Lipids (% Energy) | 17 | 17 |
Table 1. Composition and energy content of the standard chow (SC) (AIN 93G) and the fish oil (FO) (AIN 93G-based diet) diets.
Animal preparation and experimental protocol
After four weeks of the diet, the 2 groups were randomized to be sensitized and challenged with ovalbumin (albumin from chicken egg white - A5503, Sigma-Aldrich, St. Louis, MO, USA) and saline. Mice were sensitized subcutaneously with a mixture of 50 µg ovalbumin (OVA) and 5 mg aluminum hydroxide on days 0 and 14. On days 21 and 22, animals were intranasally challenged with 25 µg OVA. Control animals received saline (SAL). Animals continued to be given the respective diets during sensitization and challenge periods. The analyses were performed 24 hours after the last challenge. The experiments were done twice and data shown are representative of one experiment. In the particular case of lung function, three experiments were done and data shown are representative of two of them.
Lung function and airway hyperreactivity
Animals were anesthetized (Nembutal 60 mg/kg i.p.) and tracheotomized for pulmonary function and hyperreactivity assessment in a FinePoint R/C Buxco Platform (Buxco Electronics, Sharom, CT, USA) 24 hours after the last challenge (day 23). Airflow and transpulmonary pressure were recorded using a Buxco Pulmonary Mechanics Processing System (Buxco Electronics, Wilmington, NC, USA), which was also used to calculate airway resistance (cmH 2O/ml/s) and dynamic compliance (ml/cmH 2O). Analog signals from the computer were digitized using a Buxco analog to digital converter (Buxco Electronics). Mice were stabilized for 5 minutes, and increasing methacholine concentrations (3, 9, and 27 mg/ml) were aerosolized for 5 minutes each. Baseline resistance and dynamic compliance were assessed with aerosolized phosphate-buffered saline (PBS). The results were expressed as the mean absolute values of lung resistance and elastance (calculated as the inverse of compliance values - cmH 2O/ml) responses recorded during the 5 minutes after methacholine aerosol administration.
Bronchoalveolar lavage (BAL)
Lungs were washed via tracheal tube with PBS solution (1 ml) containing EDTA (10 mM). Samples were centrifuged at 300 x g for 10 minutes. The supernatant was used for chemokine analysis, and the pellet was resuspended in 0.25 ml PBS. Total leukocyte numbers were measured in Neubauer chambers using light microcopy after diluting the samples in Türk solution (2% acetic acid). Differential cell counts were performed with cytospin smears using the May-Grünwald Giemsa method [17].
Lung histology and morphometry
A laparotomy was performed immediately after the BAL. The abdominal aorta and vena cava were sectioned. The left lung was removed, fixed by immersion in 3% buffered formaldehyde. After fixation, the lung was cut longitudinally, imbedded in Paraplast (Sigma-Aldrich Co., St Louis, Mo., USA) and 3-µm thick sections were obtained for further analyses by means of light microscopy. Periodic acid-Schiff and Gomori Trichrome staining was performed to quantify mucus and extracellular matrix deposition. Measurements were made with video-microscopic system (LC Evolution camera, Olympus BX51 microscope) provided with an integrating eyepiece with a known area (104 µm2) at a maginification of 400X). Nine to ten distal airways per lung were analyzed using Image-Pro Plus version 7.01 software (Media Cybernetics, Silver Spring, MD, USA) and only airways (bronchiole) with dimensions fitting in the counting frame area were considered [18]. We evaluated airway inflammatory cell infiltrates with Sirius Red pH 10.2 and employed a test system made up of 100 grid lines for the analysis. A total of 10-20 fields were analyzed per lung at a final magnification of 1,000x. Eosinophils present in the airway wall were counted in three randomly selected areas and were expressed as cells/unit area (104 µm2).
Serum anti-OVA IgE and IgG1 measurement
Blood was taken by cardiac puncture under light ether anesthesia 19 days after sensitization. After blood coagulation, individual sera were collected and stored at -20oC until use. Anti-OVA IgE and IgG1 were measured by means of enzyme-linked immunosorbent assays (ELISA) (Cayman Chemical Company, Ann Arbor, Michigan, USA and BioVendor Research and Diagnostic Products, Asheville, USA, respectively) according to the instructions of the manufacturer.
Cytokine and chemokines measurement
Murine IL-4, IL-5, IL-10, IL-13, IL-17, INFγ and eotaxin-1 and -2 levels were measured in right lung tissue samples by means of ELISA technique using commercial Duo Set kits R&D Systems (Minneapolis, USA) following the instructions of the manufacturer.
Western blot
Lung tissue was homogenized as described previously [19]. Briefly, protein was quantified, and 50 µg total protein was loaded on 10% SDS-polyacrylamide gels and blotted onto nitrocellulose membranes. Nonspecific binding was blocked with 5% (w/v) skim milk powder in T-TBS for 1 hour followed by incubation with GATA-3 1:500 (50 kDa; SC-22206; Santa Cruz Biotechnology), NFκB p65 1:500 (nuclear factor kappa B; 65 kDa; SC-372; Santa Cruz Biotechnology), PPARγ 1:1000 (peroxisome proliferator activated-receptor gamma; 54 kDa; SC-7273; Santa Cruz Biotechnology) or β-actin 1:2000 (43 kDa; SC-47778; Santa Cruz Biotechnology) antibodies overnight at 4°C. Blots were then incubated with appropriate horseradish peroxidase-conjugated secondary antibodies followed by enhanced chemiluminescence detection. Band intensities were quantified by densitometry using ImageJ 1.3 software (NIH, USA).
Data analysis
The values are shown as the means and standard error of the mean (SEM). In the cases where we could confirm homocedasticity of variances, comparisons among groups were made using analysis of variance (ANOVA) followed by the Holm-Sidak post-hoc test. In each case, a P-value ≤ 0.05 was considered to be statistically significant. All of the analyses were performed using Graph Pad Prism version 6.01 for Windows (La Jolla, CA, USA).
Results
There were no differences in food intake (SC-SAL: 2.67±0.03 g SC-OVA: 2.70±0.003 g; FO-SAL: 2.78±0.004 g; FO-OVA: 2.75±0.004 g) or body mass (SC-SAL: 25.05±0.36 g SC-OVA: 24.44±0.79 g; FO-SAL: 25.13±0.84 g; FO-OVA: 24.97±0.63 g) among the experimental groups during the experiment.
Effect of FO administration on lung leukocyte recruitment
Antigen challenge of actively sensitized mice (SC-OVA) increased the total BAL leukocyte counts 24 hours after the last challenge compared with control (SC-SAL) mice (+136%, P<0.0001). This elevation was because of increased mononuclear cells (2-fold increase, P=0.0018), neutrophils (more than 400-fold increase, P<0.0001) and eosinophils (more than 500-fold increase, P<0.0001). FO intake by sensitized, challenged mice (FO-OVA) inhibited total BAL leukocyte infiltration (-52%, P=0.0002), including mononuclear cells, neutrophils and eosinophils (P=0.0029, P<0.0001 and P=0.0002, respectively) (Figure 1).
Sensitized, saline-challenged (SC-SAL); sensitized, ovalbumin-challenged (SC-OVA); sensitized, saline-challenged with fish oil (FO-SAL) and sensitized, ovalbumin-challenged with fish-oil (FO-OVA). The analyses were performed 24 hours after the last challenge. In the signaled cases, P<0.05 compared with the SC-SAL group (+) and the SC-OVA group (*) (one-way ANOVA and post-hoc Holm-Sidak test). Values are the means ± S.E.M. and are representative of 1 experiment (n=5 per group).
Lung parenchyma of the control mice (SC-SAL) were normal (Figure 2A). Histological lung evaluations of the SC-OVA mice revealed a marked peribronchiolar eosinophil accumulation (Figure 2B) compared with the SC-SAL mice. The FO intake did not alter the lung parenchyma in the FO-SAL mice (Figure 2C) but markedly inhibited the tissue eosinophil infiltration in the FO-OVA mice (Figure 2D). Quantitative morphometric analyses of lung sections demonstrated that FO markedly inhibited tissue eosinophil infiltration (P<0.0001) (Figure 2E).
Photomicrographs were taken of representative airways from (A) sensitized, saline-challenged (SC-SAL); (B) sensitized, ovalbumin-challenged (SC-OVA); (C) sensitized, saline-challenged with fish oil (FO-SAL) and (D) sensitized, ovalbumin-challenged with fish oil (FO-OVA). (E) Peribronchiolar eosinophil number was determined in lung sections by morphometric analyses. The analyses were performed 24 hours after the last challenge. Slides were stained with Sirius Red. Arrows indicate representative eosinophils. In the signaled cases, P<0.05 compared with the SC-SAL group (+) and the SC-OVA group (*) (one-way ANOVA and post-hoc Holm-Sidak test). Values are the means ± S.E.M. and are representative of 1 experiment (n=5 per group).
Effect of FO administration on lung remodeling and mucus deposition
As observed in Figure 3, lung sections stained with Gomori trichrome demonstrated that SC-SAL mice had normal lung parenchyma (Figure 3A) and that the SC-OVA mice had increased peribronchiolar matrix deposition (Figure 3B) compared with the SC-SAL mice (+ 205%, P=0.0051). No alterations were noted in the non-challenged mice that were given FO (FO-SAL) (Figure 3C). However, FO intake reduced responses in the FO-OVA mice (P=0.0099) (Figure 3D). Quantitative analyses demonstrated that FO intake prevented extracellular matrix deposition in the FO-OVA mice (Figure 3E).
Photomicrographs were taken of representative airways from (A) sensitized, saline-challenged (SC-SAL); (B) sensitized, ovalbumin-challenged (SC-OVA); (C) sensitized, saline-challenged with fish oil (FO-SAL) and (D) sensitized, ovalbumin-challenged with fish oil (FO-OVA). (E) Quantitative assessment of lung tissue fibrosis. The analyses were made 24 hours after the last challenge. The slides were stained with Gomori trichrome stain. Arrows indicate representative matrix deposition. In the signaled cases, P<0.05 compared with the SC-SAL group (+) and the SC-OVA group (*) (one-way ANOVA and post-hoc Holm-Sidak test). Values are the means ± S.E.M. and are representative of 1 experiment (n=5 per group).
To evaluate mucus production, lung histology sections were stained with periodic acid-Schiff. SC-SAL and FO-SAL mice displayed no mucus production (Figure 4A and 4C, respectively), whereas SC-OVA mice had increased mucus secretion (P<0.0001) within the airway epithelia (Figure 4B). This phenomenon was prevented in the FO-OVA mice (-72%, P<0.0001) (Figure 4D). Quantitative analyses are shown in Figure 4E.
Photomicrographs were taken of representative airways from (A) sensitized, saline-challenged (SC-SAL); (B) sensitized, ovalbumin-challenged (SC-OVA); (C) sensitized, saline-challenged with fish oil (FO-SAL) and (D) sensitized, ovalbumin-challenged with fish oil (FO-OVA). (E) Quantitative assessment of mucus production was performed by morphometric analyses. The analyses were performed 24 hours after the last challenge. Slides were stained with periodic acid-Schiff. Arrows indicate representative mucus deposition. In the signaled cases, P<0.05 compared with the SC-SAL group (+) and the SC-OVA group (*) (one-way ANOVA and post-hoc Holm-Sidak test). Values are the means ± S.E.M and are representative of 1 experiment (n=5 per group).
Effect of FO administration on antigen-induced hyperreactivity (AHR)
Antigen challenge of sensitized mice caused AHR, as demonstrated by increased lung resistance and elastance after methacholine (3-27 mg/mL) stimulation (Figure 5A and 5B, respectively) compared with control mice (SC-SAL). FO intake reduced AHR in the FO-OVA mice (Figure 5A and 5B).
Airway hyperreactivity was measured as changes that were induced by increasing methacholine concentrations 24 hours after the last antigen challenge. Sensitized, saline-challenged (SC-SAL); sensitized, ovalbumin-challenged (SC-OVA); sensitized, saline-challenged given fish oil (FO-SAL) and sensitized, ovalbumin-challenged with fish oil (FO-OVA). In the signaled cases, P<0.05 compared with the SC-SAL group (+) and the SC-OVA group (*) (one-way ANOVA and post-hoc Holm-Sidak test). Values are the means ± S.E.M. and are representative of 2 independent experiments (n=6 per group per experiment).
Effect of FO administration on serum specific anti-OVA IgE and IgG1
Naive animals showed no anti-OVA IgE and IgG1 in serum, meanwhile OVA-sensitized mice fed a SC-diet (SC group) demonstrated increased levels of both IgE and IgG1 (P=0.0001 and P<0.0001, respectively). Moreover, OVA sensitized mice fed a FO-diet (FO group) presented a reduction of 64% in serum IgE (P=0.0078) and of 83% in serum IgG1 when compared to SC group (P<0.0001). These results can be seen in Figure 6A and 6B.
Sensitized (SC) and sensitized, with fish oil (FO). In the signaled cases, P<0.05 compared with the Naive group (+) and the SC group (*) (one-way ANOVA and post-hoc Holm-Sidak test). Values are the means ± S.E.M. and are representative of 1 experiment (n=7 per group).
Effect of FO administration on lung cytokines
The lungs from OVA-challenged mice presented higher levels of IL-4 (Figure 7A), IL-5 (Figure 7C), IL-13 (Figure 7B), IL-17 (Figure 7D), eotaxin-1 (Figure 7G) and eotaxin-2 (Figure 7H) as compared to SAL-challenged animals. As shown in Figure 7, FO intake markedly reduced the levels of these pro-inflammatory and pro-fibrotic cytokines in the lung of OVA-challenge mice: IL-4 (-60%, P=0.0004), IL-5 (-50%, P=0.0002), IL-13 (-47%, P=0.0042), IL17 (-34%, P=0.0072), eotaxin-1 (-23%, P=0.0212) and eotaxin-2 (-35%, P=0.0004). No increase of IL-10 and INFγ levels were detected in the lungs of OVA-challenged mice compared to control group, and the treatment with FO did not significantly altered basal levels of both cytokines (Figure 7E and 7F).
Sensitized, saline-challenged (SC-SAL); sensitized, ovalbumin-challenged (SC-OVA); sensitized, saline-challenged given fish oil (FO-SAL) and sensitized, ovalbumin-challenged with fish oil (FO-OVA). In the signaled cases, P<0.05 compared with the SC-SAL group (+) and the SC-OVA group (*) (one-way ANOVA and post-hoc Holm-Sidak test). Values are the means ± S.E.M. and are representative of 1 experiment (n=7 per group).
Effect of FO administration on NFκB, GATA-3 and PPARγ expression
As illustrated in Figure 8A and 8B, the SC-OVA mice exhibited elevated NFκB and GATA-3 expression in whole-lung extracts compared with the SC-SAL mice (+42%, P=0.0002 and +59%, P=0.0162, respectively). FO-OVA mice had reduced NFκB (P=0.0006) (Figure 8A) and GATA-3(P=0.0410) expression (Figure 8B). FO-SAL and FO-OVA mice had increased PPARγ expression in lung extracts compared with the SC-SAL (+132%, P<0.0001) and SC-OVA (+98%, P<0.0001) mice (Figure 8C).
Sensitized, saline-challenged (SC-SAL); sensitized, ovalbumin-challenged (SC-OVA); sensitized, saline-challenged with fish oil (FO-SAL) and sensitized, ovalbumin-challenged with fish oil (FO-OVA). The results were standardized to β-actin expression and were expressed in arbitrary units (a.u.). The analyses were performed 24 hours after the last challenge. In the signaled cases, P<0.05 compared with the SC-SAL group (+) and the SC-OVA group (*) (one-way ANOVA and post-hoc Holm-Sidak test). Values are the means ± S.E.M. and are representative of 1 experiment (n=5 per group).
Discussion
In this study, we demonstrated that FO intake before and during sensitization and challenge ameliorated the inflammatory response by reducing eosinophil infiltration in the BAL fluid and lung tissue, remodeling and mucus deposition, inflammatory and pro-fibrotic cytokine production, which contributed to diminished airway hyperreactivity. In addition, FO down-regulated serum anti-OVA IgE and IgG1 production and the expression of inflammatory transcription factors GATA-3 and NFκB.
In accordance with a previous study, ovalbumin-challenged mice showed an increase in the bronchoalveolar accumulation of leukocytes as compared to controls, a response which was accounted for by elevated number of mononuclear cells, neutrophils and eosinophils [20]. Moreover, pulmonary tissue eosinophil infiltration was increased in mice, confirming previous data from the literature [21,22]. Eosinophils are major disease effectors that contribute to the release of a variety of inflammatory mediators such as cytokines, chemokines, lipid mediators and cationic proteins [23,24]. Eosinophil infiltration can be controlled by IL-5, a Th2-type cytokine [25], which is present in lung tissue from OVA-challenged mice and causes induction of eosinophils maturation in bone marrow and eosinophil traffic to the site of inflammation [24,26]. It can also be controlled by eotaxin, which is comprised of eotaxin-1 (CCL11) and eotaxin-2 (CCL24) in mice [27]. These belong to a family called CC chemokines, which are produced by epithelial cells, alveolar macrophages and dendritic cells and bind to the eotaxin receptor (CCR3) in eosinophils [25]. Eotaxin-1 and 2 are elevated in lung tissue of allergen-challenged mice, are responsible for eosinophil influx and contribute to eosinophilia [25,26]. Increased levels of such mediators, as in this study, could explain the increased eosinophils in both the BAL fluid and the lung tissue. In our study, FO consumption decreased eosinophil infiltration, which is in contrast to previous observations regarding lung inflammation in mice that received FO by gavage for 14 days [15]. This response can be associated, at least in part, with reduction of IL-5 and eotaxin-1 and -2 generation.
Asthma is also characterized by structural changes in the airways, which includes subepithelial fibrosis, epithelial damage and smooth muscle hypertrophy [17]. In histological lung sections, we noted increased extracellular matrix deposition in the SC-OVA mice [17,21]. Subepithelial/peribronchial fibrosis is characterized by extracellular matrix protein deposits beneath the basal lamina, which is controlled by the cytokines such as IL-4 and IL-13 in asthma [28]. IL-4 and IL-13 orchestrate asthma-associated inflammation and are Th2 cytokines that are produced not only by lymphocytes but also by mast cells, eosinophils and macrophages. Both cytokines are induced in ovalbumin-challenged mice and are responsible for several structural and functional disease alterations [23,28]. Therefore, IL-4 and IL-13 reductions may be a mechanism for the decreased extracellular matrix deposition in the FO-OVA group.
Goblet cell hyperplasia and mucus hypersecretion are also important features of asthma. In our study we found elevated bronchiolar mucus deposition, confirming a previous study [21]. Airway goblet cells secrete mucin into the airway lumen in response to a variety of stimuli such as leukotrienes, IL-4 and IL-13. FO diminishes mucus deposition [15]. Thus, our findings of reduced IL-4 and IL-13 in the FO-OVA group could explain this reduced mucus secretion.
As expected, the ovalbumin-challenged mice (SC-OVA group) had elevated airway hyperreactivity, which is a major feature of asthma. AHR is an immoderate airway response to several allergens, although the causes underlying this condition are not well understood [29]. Some authors indicate that eosinophil infiltration has an important role in the development of AHR [30], while others demonstrate a close association between AHR and T helper lymphocytes [29]. Moreover, hyperreactivity is caused by a direct effect of IL-13 on airway smooth muscle [31]. In contrast to the study from Wood and colleagues, we report that FO intake improved resistance and elastance [15]. Because some possible AHR causes (i.e., leukocyte infiltration and alterations in IL-13-stimulated airway smooth muscle) are diminished in the FO-OVA mice, we expected reduced airway hyperreactivity in the mice that had consumed FO.
More recently, a distinct lineage of T helper cells has been described (Th17 cells) which produce a variety of cytokines, including IL-17 [32], which were shown to induce tissue remodeling and AHR [33]. Thus, diminished levels of IL-17 in lungs of FO-OVA group could explain the reduction of tissue remodeling and AHR.
The production of IL-4 and IL-13 by Th2 cells is known to control the further production of IgE antibody [34,35], which is known to bind to high affinity receptor (FceRI) mainly presented on mast cells [36]. These cells activation leads to the release of Th2-type cytokines such as IL-5 and IL13, which have the ability to induce eosinophil accumulation [35,37] by means of regulation of adhesion molecules expression and cell locomotory activity [36]. Besides that, IgG1 is also induced by Th2 cytokines like IL-4 and is cytophillic to mast cells [38,39]. In this study we showed that OVA allergic mice exhibited high levels of specific serum anti-OVA IgE and IgG1, a response suppressed under conditions of FO administration. The augmentation of serum levels of IgE and IgG1 under conditions of allergen sensitization has been shown previously [40–42]. Our data are in line with previous report showing that IgE production was reduced by FO in primary human B cells in vitro [10] and that both IgE and IgG1 were diminished after FO administration to OVA-sensitized mice [43]. The reduction in OVA-specific antibodies shows that FO affects the sensitization phase and that this could be a possible explanation for the reduced inflammatory response noted in FO-OVA group.
Mice that were genetically modified to produce greater amounts of endogenous n-3 PUFA displayed less leukocyte infiltration and mucus production in the lungs, lower total leukocyte and eosinophil number in the BAL fluid and reduced airway resistance [44]. In a previous study, using maternal protein restriction diet as a model, we observed that offspring that received FO in their diet (at the same dose of this study) during postnatal life had improved metabolic and morphological parameters in adulthood [45]. The FO dose that was given in this study was higher than that of other one using OVA-challenged mice, which demonstrated that FO might be incorporated into mouse lung tissue in a dose- and time-dependent manner [7]. FO includes 12.9% EPA and 12% DHA, totaling a content of almost 25% of these n-3 PUFA, normally seen in FO [11]. In addition, FO containing 18% EPA and 12% DHA was also given to animals and showed suppressive effect on allergen-induced oxidative stress [15], indicating that both percentages of EPA and DHA contribute to the beneficial effect of FO [46]. Thus, we can speculate that differences in the dose regimen and administration via may contribute to explain the discrepancy noted in our findings as compared to others.
There are few studies correlating EPA or DHA alone in preventing the development of allergic airway disease. The amelioration of bronchial hyperreactivity and cellular infiltration was noted under conditions of DHA aerosolization during challenge period. Another study using a DHA-derivate demonstrated beneficial effects in inflammatory response. In fact, a study with rhinovuris-infected cultured airway epithelial cells showed that only DHA had a potential role to suppress airway inflammation, while EPA presented no effects. On the other hand, in LPS-induced human asthmatic alveolar macrophage cells, the anti-inflammatory effects of EPA were much greater than effects of DHA. These data demonstrate that DHA seems to have a more expressive effect when compared to EPA despite lacking of consensus.
EPA and DHA can modulate inflammatory processes [47]. Eicosanoid lipid mediators are produced from cell membrane arachidonic acid degradation and have an important role in asthma. The 2-series prostaglandins (PG2) are produced by the enzyme cycloxygenase-2 (COX-2), and the 4-series leukotrienes (LT4) are produced by 5-lipoxygenase (5-LOX) [47]. PGD2 is secreted by mast cells and is important for the acute asthmatic airway response and inflammatory cell recruitment [48]. PGE2 has both inflammatory and anti-inflammatory effects [47]. LTB4 is implicated in chemoatraction and neutrophil activation [49]. Cysteinyl-leukotrienes (i.e., LTC4, LTD4 and LTE4) cause mucus hypersecretion and eosinophil airway infiltration [15]. N-3 PUFA intake alters cellular membrane fatty acid content [50], leading to decreased PG2 and LT4 production and enhanced PG3 and LT5 production, which has less potent inflammatory activity [11,14]. LTB5 has less chemotactic activity and fewer aggregating properties than LTB4 [14]. In addition, PGD3 inhibits the action of PGD2 [51]. In our study, we hypothesized that FO intake altered the cell membrane lipid profile and consequently the proportional production of PG2-LT4/PG3-LT5, thus decreasing the response to allergen.
In this study we showed that treatment with FO did not cause any alteration in the levels of IL-10 and INFγ in the lung tissue of OVA-challenged mice, indicating that the suppressive effect of FO on the allergic lung response in mice does not seem to be dependent on the production of the anti-inflammatory cytokines or to a shift towards a Th1 prolife.
EPA and DHA, in addition to their effects mentioned above, directly control the expression of transcription factors [11]. GATA-3 is responsible for the development and differentiation of CD4+ lymphocytes [52]. DHA diminished GATA-3 expression in a mouse model of experimental autoimmune encephalomyelitis [53], in accordance with our data. NFκB is expressed in inflammatory cells, and its activation causes the production of several inflammatory proteins including cytokines and COX-2. To be activated, NFκB must be disassociated from its inhibitory subunit IκB by phosphorylation [54]. FO consumption decreases IκB phosphorylation and diminishes NFκB activation and inflammatory protein production [55]. In our study, we found that elevated NFκB expression in OVA-challenged mice could explain the increase in inflammatory cytokine and eicosanoid expression in these animals. Moreover, FO appears to modulate NFκB expression in the FO-OVA group, attenuating inflammatory response.
PPARγ can also be modulated by FO [11]. Recent studies demonstrated that PPARγ agonists reduce AHR, eosinophilia and Th2 cytokine and chemokine levels [56,57]. PPARγ binds to NFκB, thus blocking its nuclear translocation and inhibiting its pro-inflammatory properties [58]. It could be postulated that FO intake diminished inflammatory mediator production by reduced NFκB activation and increased PPARγ activity in this experiment.
In conclusion, our results show that prophylactic FO intake reduced airway hyperreactivity and impaired eosinophil inflammation, mucus production, peribronchiolar fibrosis and cytokine production in sensitized antigen-challenged mice using a mechanism that is associated with down-regulation of NFκB and GATA-3 and the up-regulation of PPARγ expression. OVA-specific serum IgE and IgG1 were also sensitive to FO. Altogether, our findings show that FO has beneficial effect to prevent systemic sensitization, and indicate that FO can be considered as a potent new prophylactic adjuvant for the asthma prevention.
Acknowledgments
The authors thank Miss Ana Carolina Santos de Arantes, Mr. Rodrigo Azevedo, Mr. Rafael Martins, Mrs. Thatiany Marinho, and Mrs. Aline Penna for their technical assistance.
Author Contributions
Conceived and designed the experiments: TLB PRS MBA. Performed the experiments: TLB TTF JBD. Analyzed the data: TLB MAM PRS MBA. Contributed reagents/materials/analysis tools: MAM PRS MBA. Wrote the manuscript: TLB PRS MBA.
References
- 1.
(2011)The Global Asthma Report 2011 Paris, France: The International Union Against Tuberculosis and Lung Disease.
- 2. Girodet PO, Ozier A, Bara I, Tunon de Lara JM, Marthan R et al. (2011) Airway remodeling in asthma: new mechanisms and potential for pharmacological intervention. Pharmacol Ther 130: 325-337. doi:https://doi.org/10.1016/j.pharmthera.2011.02.001. PubMed: 21334378.
- 3. Oliphant CJ, Barlow JL, McKenzie AN (2011) Insights into the initiation of type 2 immune responses. Immunology 134: 378-385. doi:https://doi.org/10.1111/j.1365-2567.2011.03499.x. PubMed: 22044021.
- 4. Durrani SR, Viswanathan RK, Busse WW (2011) What effect does asthma treatment have on airway remodeling? Current perspectives. J Allergy Clin Immunol 128: 439-448; quiz 449-450 doi:https://doi.org/10.1016/j.jaci.2011.06.002. PubMed: 21752441.
- 5. Galli C, Calder PC (2009) Effects of fat and fatty acid intake on inflammatory and immune responses: a critical review. Ann Nutr Metab 55: 123-139. doi:https://doi.org/10.1159/000228999. PubMed: 19752539.
- 6. Hulbert AJ, Turner N, Storlien LH, Else PL (2005) Dietary fats and membrane function: implications for metabolism and disease. Biol Rev Camb Philos Soc 80: 155-169. doi:https://doi.org/10.1017/S1464793104006578. PubMed: 15727042.
- 7. Yin H, Liu W, Goleniewska K, Porter NA, Morrow JD et al. (2009) Dietary supplementation of omega-3 fatty acid-containing fish oil suppresses F2-isoprostanes but enhances inflammatory cytokine response in a mouse model of ovalbumin-induced allergic lung inflammation. Free Radic Biol Med 47: 622-628. doi:https://doi.org/10.1016/j.freeradbiomed.2009.05.033. PubMed: 19501157.
- 8. Aguila MB, Pinheiro AR, Aquino JC, Gomes AP, Mandarim-de-Lacerda CA (2005) Different edible oil beneficial effects (canola oil, fish oil, palm oil, olive oil, and soybean oil) on spontaneously hypertensive rat glomerular enlargement and glomeruli number. Prostaglandins Other Lipid Mediat 76: 74-85. doi:https://doi.org/10.1016/j.prostaglandins.2004.12.003. PubMed: 15967163.
- 9.
Aguila MB, Mandarim-de-Lacerda CA (2010) Beneficial effects of olive oil compared with fish, canola, palm and soybean oils on cardiovascular and renal adverse remodeling due to hypertension and diabetes in rat. In: VR PreedyRR Watson. Olives and oile oil in health and disease prevention. Oxford: Academic Press. pp. 787-794.
- 10. Weise C, Hilt K, Milovanovic M, Ernst D, Rühl R et al. (2011) Inhibition of IgE production by docosahexaenoic acid is mediated by direct interference with STAT6 and NFkappaB pathway in human B cells. J Nutr Biochem 22: 269-275. doi:https://doi.org/10.1016/j.jnutbio.2010.02.004. PubMed: 20576420.
- 11. Calder PC (2012) Mechanisms of action of (n-3) fatty acids. J Nutr 142: 592S-599S. doi:https://doi.org/10.3945/jn.111.155259. PubMed: 22279140.
- 12. Covar R, Gleason M, Macomber B, Stewart L, Szefler P et al. (2010) Impact of a novel nutritional formula on asthma control and biomarkers of allergic airway inflammation in children. Clin Exp Allergy 40: 1163-1174. doi:https://doi.org/10.1111/j.1365-2222.2010.03523.x. PubMed: 20545703.
- 13. Biltagi MA, Baset AA, Bassiouny M, Kasrawi MA, Attia M (2009) Omega-3 fatty acids, vitamin C and Zn supplementation in asthmatic children: a randomized self-controlled study. Acta Paediatr 98: 737-742. doi:https://doi.org/10.1111/j.1651-2227.2008.01213.x. PubMed: 19154523.
- 14. Mickleborough TD, Lindley MR, Ionescu AA, Fly AD (2006) Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma. Chest 129: 39-49. doi:https://doi.org/10.1378/chest.129.1.39. PubMed: 16424411.
- 15. Wood LG, Hazlewood LC, Foster PS, Hansbro PM (2010) Lyprinol reduces inflammation and improves lung function in a mouse model of allergic airways disease. Clin Exp Allergy 40: 1785-1793. doi:https://doi.org/10.1111/j.1365-2222.2010.03503.x. PubMed: 20412134.
- 16. Reeves PG, Nielsen FH, Fahey GC Jr. (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123: 1939-1951. PubMed: 8229312.
- 17. Antunes MA, Abreu SC, Silva AL, Parra-Cuentas ER, Ab’saber AM et al. (2010) Sex-specific lung remodeling and inflammation changes in experimental allergic asthma. J Appl Physiol 109: 855-863. doi:https://doi.org/10.1152/japplphysiol.00333.2010. PubMed: 20634353.
- 18. Arantes-Costa FM, Lopes FD, Toledo AC, Magliarelli-Filho PA, Moriya HT et al. (2008) Effects of residual oil fly ash (ROFA) in mice with chronic allergic pulmonary inflammation. Toxicol Pathol 36: 680-686. doi:https://doi.org/10.1177/0192623308317427. PubMed: 18477768.
- 19. Churg A, Wang RD, Tai H, Wang X, Xie C et al. (2004) Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 170: 492-498. doi:https://doi.org/10.1164/rccm.200404-511OC. PubMed: 15184206.
- 20. Queto T, Vasconcelos ZF, Luz RA, Anselmo C, Guiné AA et al. (2011) G-CSF suppresses allergic pulmonary inflammation, downmodulating cytokine, chemokine and eosinophil production. Life Sci 88: 830-838. doi:https://doi.org/10.1016/j.lfs.2011.03.001. PubMed: 21396376.
- 21. Saraiva SA, Silva AL, Xisto DG, Abreu SC, Silva JD et al. (2011) Impact of obesity on airway and lung parenchyma remodeling in experimental chronic allergic asthma. Respir Physiol Neurobiol 177: 141-148. doi:https://doi.org/10.1016/j.resp.2011.03.019. PubMed: 21453798.
- 22. Nabe T, Ikedo A, Hosokawa F, Kishima M, Fujii M et al. (2012) Regulatory role of antigen-induced interleukin-10, produced by CD4(+) T cells, in airway neutrophilia in a murine model for asthma. Eur J Pharmacol 677: 154-162. doi:https://doi.org/10.1016/j.ejphar.2011.12.020. PubMed: 22209878.
- 23. Olsen PC, Ferreira TP, Serra MF, Farias-Filho FA, Fonseca BP et al. (2011) Lidocaine-derivative JMF2-1 prevents ovalbumin-induced airway inflammation by regulating the function and survival of T cells. Clin Exp Allergy 41: 250-259. doi:https://doi.org/10.1111/j.1365-2222.2010.03580.x. PubMed: 20874831.
- 24. Uhm TG, Kim BS, Chung IY (2012) Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma. Allergy Asthma Immunol Res 4: 68-79. doi:https://doi.org/10.4168/aair.2012.4.2.68. PubMed: 22379601.
- 25. Ochkur SI, Jacobsen EA, Protheroe CA, Biechele TL, Pero RS et al. (2007) Coexpression of IL-5 and eotaxin-2 in mice creates an eosinophil-dependent model of respiratory inflammation with characteristics of severe asthma. J Immunol 178: 7879-7889. PubMed: 17548626.
- 26. Serra MF, Anjos-Valotta EA, Olsen PC, Couto GC, Jurgilas PB et al. (2012) Nebulized lidocaine prevents airway inflammation, peribronchial fibrosis, and mucus production in a murine model of asthma. Anesthesiology 117: 580-591. doi:https://doi.org/10.1097/ALN.0b013e31826687d5. PubMed: 22846675.
- 27. Crapster-Pregont M, Yeo J, Sanchez RL, Kuperman DA (2012) Dendritic cells and alveolar macrophages mediate IL-13-induced airway inflammation and chemokine production. J Allergy Clin Immunol 129: 1621-1627 e1623 doi:https://doi.org/10.1016/j.jaci.2012.01.052. PubMed: 22365581.
- 28. Takayama G, Arima K, Kanaji T, Toda S, Tanaka H et al. (2006) Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 118: 98-104. doi:https://doi.org/10.1016/j.jaci.2006.02.046. PubMed: 16815144.
- 29. Zosky GR, Larcombe AN, White OJ, Burchell JT, von Garnier C et al. (2009) Airway hyperresponsiveness is associated with activated CD4+ T cells in the airways. Am J Physiol Lung Cell Mol Physiol 297: L373-L379. doi:https://doi.org/10.1152/ajplung.00053.2009. PubMed: 19482896.
- 30. Takeda K, Haczku A, Lee JJ, Irvin CG, Gelfand EW (2001) Strain dependence of airway hyperresponsiveness reflects differences in eosinophil localization in the lung. Am J Physiol Lung Cell Mol Physiol 281: L394-L402. PubMed: 11435214.
- 31. Jiang H, Xie Y, Abel PW, Toews ML, Townley RG et al. (2012) Targeting phosphoinositide 3-kinase gamma in airway smooth muscle cells to suppress interleukin-13-induced mouse airway hyperresponsiveness. J Pharmacol Exp Ther.
- 32. Lim H, Kim YU, Drouin SM, Mueller-Ortiz S, Yun K et al. (2012) Negative regulation of pulmonary Th17 responses by C3a anaphylatoxin during allergic inflammation in mice. PLOS ONE 7: e52666. doi:https://doi.org/10.1371/journal.pone.0052666. PubMed: 23285141.
- 33. Al-Muhsen S, Letuve S, Vazquez-Tello A, Pureza MA, Al-Jahdali H et al. (2013) Th17 cytokines induce pro-fibrotic cytokines release from human eosinophils. Respir Res 14: 34. doi:https://doi.org/10.1186/1465-9921-14-34. PubMed: 23496774.
- 34. Hawrylowicz CM, O’Garra A (2005) Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 5: 271-283. doi:https://doi.org/10.1038/nri1589. PubMed: 15775993.
- 35. Xue L, Barrow A, Pettipher R (2009) Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells. Clin Exp Immunol 156: 126-133. doi:https://doi.org/10.1111/j.1365-2249.2008.03871.x. PubMed: 19220324.
- 36. Chai OH, Han EH, Lee HK, Song CH (2011) Mast cells play a key role in Th2 cytokine-dependent asthma model through production of adhesion molecules by liberation of TNF-alpha. Exp Mol Med 43: 35-43. doi:https://doi.org/10.3858/emm.2011.43.1.004. PubMed: 21169725.
- 37. Pettipher R, Vinall SL, Xue L, Speight G, Townsend ER et al. (2012) Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. J Pharmacol Exp Ther 340: 473-482. doi:https://doi.org/10.1124/jpet.111.187203. PubMed: 22106101.
- 38. Ghosh S, Hoselton SA, Schuh JM (2012) mu-chain-deficient mice possess B-1 cells and produce IgG and IgE, but not IgA, following systemic sensitization and inhalational challenge in a fungal asthma model. J Immunol 189: 1322-1329. doi:https://doi.org/10.4049/jimmunol.1200138. PubMed: 22732592.
- 39. Kaplan C, Valdez JC, Chandrasekaran R, Eibel H, Mikecz K et al. (2002) Th1 and Th2 cytokines regulate proteoglycan-specific autoantibody isotypes and arthritis. Arthritis Res 4: 54-58. doi:https://doi.org/10.1186/ar497. PubMed: 11879537.
- 40. Peebles RS Jr., Hashimoto K, Sheller JR, Moore ML, Morrow JD et al. (2005) Allergen-induced airway hyperresponsiveness mediated by cyclooxygenase inhibition is not dependent on 5-lipoxygenase or IL-5, but is IL-13 dependent. J Immunol 175: 8253-8259. PubMed: 16339565.
- 41. Shin IS, Lee MY, Lim HS, Ha H, Seo CS et al. (2012) An Extract of Crataegus pinnatifida Fruit Attenuates Airway Inflammation by Modulation of Matrix Metalloproteinase-9 in Ovalbumin Induced Asthma. PLOS ONE 7: e45734. doi:https://doi.org/10.1371/journal.pone.0045734. PubMed: 23029210.
- 42. Volkov A, Hagner S, Löser S, Alnahas S, Raifer H et al. (2013) beta5i Subunit Deficiency of the Immunoproteasome Leads to Reduced Th2 Response in OVA Induced Acute Asthma. PLOS ONE 8: e60565. doi:https://doi.org/10.1371/journal.pone.0060565. PubMed: 23593249.
- 43. de Matos OG, Amaral SS, Pereira da Silva PE, Perez DA, Alvarenga DM et al. (2012) Dietary supplementation with omega-3-PUFA-rich fish oil reduces signs of food allergy in ovalbumin-sensitized mice. Clin Dev Immunol, 2012: 2012: 236564. PubMed: 22162714.
- 44. Bilal S, Haworth O, Wu L, Weylandt KH, Levy BD et al. (2011) Fat-1 transgenic mice with elevated omega-3 fatty acids are protected from allergic airway responses. Biochim Biophys Acta 1812: 1164-1169. doi:https://doi.org/10.1016/j.bbadis.2011.05.002. PubMed: 21616147.
- 45. Bringhenti I, Schultz A, Rachid T, Bomfim MA, Mandarim-de-Lacerda CA et al. (2011) An early fish oil-enriched diet reverses biochemical, liver and adipose tissue alterations in male offspring from maternal protein restriction in mice. J Nutr Biochem 22: 1009-1014. doi:https://doi.org/10.1016/j.jnutbio.2010.08.013. PubMed: 21190827.
- 46. Bhattacharya A, Rahman MM, Sun D, Lawrence R, Mejia W et al. (2005) The combination of dietary conjugated linoleic acid and treadmill exercise lowers gain in body fat mass and enhances lean body mass in high fat-fed male Balb/C mice. J Nutr 135: 1124-1130. PubMed: 15867292.
- 47. Calder PC (2006) n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83: 1505S-1519S. PubMed: 16841861.
- 48. Larsson AK, Hagfjärd A, Dahlén SE, Adner M (2011) Prostaglandin D(2) induces contractions through activation of TP receptors in peripheral lung tissue from the guinea pig. Eur J Pharmacol 669: 136-142. doi:https://doi.org/10.1016/j.ejphar.2011.07.046. PubMed: 21872585.
- 49. Bhavsar PK, Levy BD, Hew MJ, Pfeffer MA, Kazani S et al. (2010) Corticosteroid suppression of lipoxin A4 and leukotriene B4 from alveolar macrophages in severe asthma. Respir Res 11: 71. doi:https://doi.org/10.1186/1465-9921-11-71. PubMed: 20529300.
- 50. Dawczynski C, Hackermeier U, Viehweger M, Stange R, Springer M et al. (2011) Incorporation of n-3 PUFA and gamma-linolenic acid in blood lipids and red blood cell lipids together with their influence on disease activity in patients with chronic inflammatory arthritis--a randomized controlled human intervention trial. Lipids Health Dis 10: 130. doi:https://doi.org/10.1186/1476-511X-10-130. PubMed: 21816071.
- 51. Tull SP, Yates CM, Maskrey BH, O’Donnell VB, Madden J et al. (2009) Omega-3 Fatty acids and inflammation: novel interactions reveal a new step in neutrophil recruitment. PLOS Biol 7: e1000177. PubMed: 19707265.
- 52. Lu Y, Malmhäll C, Sjöstrand M, Rådinger M, O’Neil SE et al. (2011) Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORgammat cells in allergic inflammation, local lung distribution and chemokine gene expression. PLOS ONE 6: e19889. doi:https://doi.org/10.1371/journal.pone.0019889. PubMed: 21625544.
- 53. Kong W, Yen JH, Ganea D (2011) Docosahexaenoic acid prevents dendritic cell maturation, inhibits antigen-specific Th1/Th17 differentiation and suppresses experimental autoimmune encephalomyelitis. Brain Behav Immun 25: 872-882. doi:https://doi.org/10.1016/j.bbi.2010.09.012. PubMed: 20854895.
- 54. Perkins ND (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8: 49-62. doi:https://doi.org/10.1038/nrm2083. PubMed: 17183360.
- 55. Novak TE, Babcock TA, Jho DH, Helton WS, Espat NJ (2003) NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol 284: L84-L89. PubMed: 12388359.
- 56. Woerly G, Honda K, Loyens M, Papin JP, Auwerx J et al. (2003) Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med 198: 411-421. doi:https://doi.org/10.1084/jem.20021384. PubMed: 12900517.
- 57. Lee KS, Park SJ, Kim SR, Min KH, Jin SM et al. (2006) Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor gamma in a murine model of toluene diisocyanate-induced asthma. J Immunol 177: 5248-5257. PubMed: 17015710.
- 58. Vanden Berghe W, Vermeulen L, Delerive P, De Bosscher K, Staels B et al. (2003) A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. Adv Exp Med Biol 544: 181-196. doi:https://doi.org/10.1007/978-1-4419-9072-3_22. PubMed: 14713228.